Susan Y. Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Susan Y. Wu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adil Daud
Department of Medicine University of California San Francisco California USA
1 shared publication - Lauren Boreta
University of California San Francisco
1 shared publication - Lisa Singer
Harvard Medical School, Boston, MA
1 shared publication - Melody J. Xu
Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, Suite H-1031, San Francisco, CA, 94115, USA
1 shared publication - Michael A. Garcia
Department of Radiation Oncology, University of California San Francisco
1 shared publication - Shannon E. Fogh
S.E. Foghis associate professor, Department of Radiation Oncology, University of California San Francisco School of Medicine, San Francisco, California
1 shared publication
Latest Publications
- Open Access
- 23 March 2019
- Published by Springer Nature in BMC Palliative Care
- Vol. 18 (1) , 1-8
Palliative radiotherapy near the end of life
A significant proportion of patients with advanced cancer undergo palliative radiotherapy (RT) within their last 30 days of life. This study characterizes palliative RT at our institution and aims to identify patients who may experience limited benefit from RT due to imminent mortality. Five hundred and-eighteen patients treated with external beam RT to a site of metastatic disease between 2012 and 2016 were included. Mann-Whitney U and chi-squared tests were used to identify factors associated with RT within 30 days of death (D30RT). Median age at RT was 63 years (IQR 54–71). Median time from RT to death was 74 days (IQR 33–174). One hundred and twenty-five patients (24%) died within 30 days of RT. D30RT was associated with older age at RT (64 vs. 62 years, p = 0.04), shorter interval since diagnosis (14 vs. 31 months, p < 0.001), liver metastasis (p = 0.02), lower KPS (50 vs. 70, p < 0.001), lower BMI (22 vs. 24, p = 0.001), and inpatient status at consult (56% vs. 26%, p < 0.001). Patients who died within 30 days of RT were less likely to have hospice involved in their care (44% vs. 71%, p = 0.001). D30RT was associated with higher Chow and TEACHH scores at consult (p < 0.001 for both). Twenty-four percent of patients received palliative RT within 30 days of death. Additional tools are necessary to help physicians identify patients who would benefit from short treatment courses or alternative interventions to maximize quality at the end of life.
- 23 March 2019
- Published by Springer Nature in BMC Palliative Care
- Vol. 18 (1) , 1-8
Open AccessPalliative radiotherapy near the end of life
A significant proportion of patients with advanced cancer undergo palliative radiotherapy (RT) within their last 30 days of life. This study characterizes palliative RT at our institution and aims to identify patients who may experience limited benefit from RT due to imminent mortality. Five hundred and-eighteen patients treated with external beam RT to a site of metastatic disease between 2012 and 2016 were included. Mann-Whitney U and chi-squared tests were used to identify factors associated with RT within 30 days of death (D30RT). Median age at RT was 63 years (IQR 54–71). Median time from RT to death was 74 days (IQR 33–174). One hundred and twenty-five patients (24%) died within 30 days of RT. D30RT was associated with older age at RT (64 vs. 62 years, p = 0.04), shorter interval since diagnosis (14 vs. 31 months, p < 0.001), liver metastasis (p = 0.02), lower KPS (50 vs. 70, p < 0.001), lower BMI (22 vs. 24, p = 0.001), and inpatient status at consult (56% vs. 26%, p < 0.001). Patients who died within 30 days of RT were less likely to have hospice involved in their care (44% vs. 71%, p = 0.001). D30RT was associated with higher Chow and TEACHH scores at consult (p < 0.001 for both). Twenty-four percent of patients received palliative RT within 30 days of death. Additional tools are necessary to help physicians identify patients who would benefit from short treatment courses or alternative interventions to maximize quality at the end of life.
- Open Access
- 30 May 2018
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 43
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series
Background Patients with metastatic Merkel cell carcinoma (mMCC) who experience disease progression on immunotherapy have limited additional standard options. Given evidence of synergism between radiation therapy (RT) and immunotherapy, two patients progressing on PD-1 inhibition were referred for short-course RT. Case presentation Two patients were found to have progressive mMCC on PD-1 inhibitor therapy and were treated with single-fraction palliative RT. Both patients were observed to have local control at irradiated regions, as well as durable abscopal response at unirradiated, out-of-field, sites of metastatic disease. Conclusions Short-course RT is a compelling strategy that could be a means to augment response in patients with mMCC who show progression on immune checkpoint blockade. Ongoing clinical trials are investigating the relationship between RT and immunotherapy in mMCC.
- 30 May 2018
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 6 (1) , 43
Open AccessIn-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series
Background Patients with metastatic Merkel cell carcinoma (mMCC) who experience disease progression on immunotherapy have limited additional standard options. Given evidence of synergism between radiation therapy (RT) and immunotherapy, two patients progressing on PD-1 inhibition were referred for short-course RT. Case presentation Two patients were found to have progressive mMCC on PD-1 inhibitor therapy and were treated with single-fraction palliative RT. Both patients were observed to have local control at irradiated regions, as well as durable abscopal response at unirradiated, out-of-field, sites of metastatic disease. Conclusions Short-course RT is a compelling strategy that could be a means to augment response in patients with mMCC who show progression on immune checkpoint blockade. Ongoing clinical trials are investigating the relationship between RT and immunotherapy in mMCC.